{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:20:47Z","timestamp":1788355247547,"version":"build-2803163510"},"reference-count":49,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n                  <jats:p>\n                    Drug-induced liver injury (DILI) is a significant concern during antituberculosis (anti-TB) treatment, and its association with diabetes mellitus (DM) remains inconsistent. This study investigated whether DM influences anti-TB DILI occurrence in Chinese patients. A prospective cohort study enrolled patients receiving anti-TB treatment at four hospitals. Patients were grouped by DM status and followed up until treatment completion. Propensity score matching (PSM) was performed at a 1:1 ratio to ensure comparability. Multivariate Cox regression analysis was used to identify risk factors for DILI. Among 3,952 TB patients (759 with DM), 522 developed DILI. No significant difference was observed in the incidence of DILI between DM and non-DM patients (14.6% versus 12.9%,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.333), and Kaplan\u2013Meier analysis yielded similar results (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.317). After PSM, 350 cases were included in each group. Glycated hemoglobin data were available for 122 DM and 64 non-DM patients, with median levels of 7.8% and 5.5% at diagnosis and 7.1% and 5.5% at the end of therapy, respectively. Multivariate analysis showed that DM comorbidity did not increase DILI risk (hazard ratio [HR] = 0.921, 95% CI = 0.705\u20131.202,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.544). Preventive use of hepatoprotective drugs significantly reduced DILI risk (HR = 0.622, 95% CI = 0.470\u20130.823,\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001), whereas elevated baseline aspartate aminotransferase (AST) levels increased DILI risk (HR = 1.013, 95% CI = 1.006\u20131.021,\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001). In conclusion, anti-TB DILI is not associated with DM comorbidity but is related to the preventive use of hepatoprotective drugs and baseline AST levels.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.25-0699","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:17:35Z","timestamp":1783444655000},"page":"475-482","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Diabetes Mellitus on Drug-Induced Liver Injury during Antituberculosis Therapy: A Prospective Cohort Study"],"prefix":"10.4269","volume":"115","author":[{"given":"Ruina","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Control and Prevention, Changshu Center for Disease Control and Prevention, Suzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The People\u2019s Hospital of Taixing, Taixing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiu","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, The Third People\u2019s Hospital of Zhenjiang Affiliated to Jiangsu University, Zhenjiang, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Jurong Hospital Affiliated to Jiangsu University, Jurong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, The Second People\u2019s Hospital of Changshu, Changshu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","article-title":"Global Tuberculosis Reports 2024.","year":"2024"},{"key":"b2","article-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment and Care.","year":"2025"},{"issue":"4","key":"b3","series-title":"Lancet Respir Med","first-page":"383","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis.","volume":"8","author":"Lan","year":"2020"},{"issue":"11","key":"b4","series-title":"Am J Respir Crit Care Med","first-page":"1472","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.","volume":"167","author":"Yee","year":"2003"},{"issue":"4","key":"b5","series-title":"Clin Infect Dis","first-page":"488","article-title":"Hepatotoxicity of rifampin\u2013pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.","volume":"39","author":"van Hest","year":"2004"},{"issue":"5","key":"b6","series-title":"Int J Tuberc Lung Dis","first-page":"534","article-title":"Severe hepatotoxicity due to anti-tuberculosis drugs in Spain.","volume":"9","author":"Tost","year":"2005"},{"issue":"4","key":"b7","series-title":"Pharmacol Res","first-page":"353","article-title":"Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.","volume":"51","author":"Sharifzadeh","year":"2005"},{"key":"b8","series-title":"Diabetes Res Clin Pract","first-page":"109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.","volume":"183","author":"Sun","year":"2022"},{"key":"b9","series-title":"IDF Diabetes Atlas","year":"2025"},{"issue":"6","key":"b10","series-title":"Curr Drug Targets","first-page":"493","article-title":"Activated T lymphocytes in type 2 diabetes: Implications from in\u00a0vitro studies.","volume":"4","author":"Stentz","year":"2003"},{"issue":"4","key":"b11","series-title":"Metabolism","first-page":"492","article-title":"Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance.","volume":"63","author":"van Beek","year":"2014"},{"issue":"5","key":"b12","series-title":"Exp Biol Med (Maywood)","first-page":"556","article-title":"High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus.","volume":"237","author":"Guo","year":"2012"},{"issue":"11","key":"b13","series-title":"PLoS One","first-page":"e0187967","article-title":"Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis.","volume":"12","author":"Al-Rifai","year":"2017"},{"issue":"2","key":"b14","series-title":"Rev Peru Med Exp Salud Publica","first-page":"254","article-title":"Situation of the tuberculosis-diabetes comorbidity in adults in Peru: 2016\u20132018.","volume":"38","author":"Ugarte-Gil","year":"2021"},{"key":"b15","series-title":"Front Med (Lausanne)","first-page":"1245316","article-title":"The association between type 2 diabetes and pulmonary cavitation revealed among IGRA-positive tuberculosis patients.","volume":"10","author":"Yang","year":"2023"},{"key":"b16","series-title":"Med Theory Pract","first-page":"2475","article-title":"Risk factors and prevention strategies for anti-tuberculosis drug-induced hepatotoxicity","volume":"28","author":"Huang","year":"2015"},{"key":"b17","series-title":"Risk Factors for Hepatotoxicity in Tuberculosis Patients with Comorbid Diabetes Mellitus and the Correlation with Glycolipid Metabolism and Immune-Inflammatory Profiles","author":"Lu","year":"2020"},{"issue":"17","key":"b18","series-title":"Circulation","first-page":"2735","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.","volume":"112","author":"Grundy","year":"2005"},{"issue":"2","key":"b19","series-title":"Biomed Environ Sci","first-page":"139","article-title":"Prevalence and risk factors associated with adverse drug reactions among previously treated tuberculosis patients in China","volume":"30","author":"Han","year":"2017"},{"issue":"1","key":"b20","series-title":"BMC Infect Dis","first-page":"118","article-title":"Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.","volume":"17","author":"Al-Shaer","year":"2017"},{"key":"b21","series-title":"PLoS One","first-page":"e0286306","article-title":"Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?","volume":"18","author":"Freire","year":"2023"},{"key":"b22","series-title":"BMC Public Health","first-page":"267","article-title":"Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).","volume":"10","author":"Xia","year":"2010"},{"issue":"3","key":"b23","series-title":"BMJ Open","first-page":"e027321","article-title":"Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: A protocol for a prospective observational study.","volume":"9","author":"Yang","year":"2019"},{"key":"b24","article-title":"WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis.","year":"2025"},{"key":"b25","series-title":"Chin J Pract Intern Med","first-page":"668","article-title":"Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 edition) (part 1)","volume":"41","year":"2021"},{"key":"b26","series-title":"Chin J Tuberc Respir Dis","first-page":"1069","article-title":"Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version).","volume":"47","author":"Branch","year":"2024"},{"issue":"1","key":"b27","series-title":"Sci Rep","first-page":"14311","article-title":"Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: A nested case-control study.","volume":"9","author":"Chen","year":"2019"},{"issue":"20","key":"b28","series-title":"Medicine (Baltimore)","first-page":"e38273","article-title":"Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.","volume":"103","author":"Shi","year":"2024"},{"key":"b29","series-title":"Med Sci Monit","first-page":"e920350","article-title":"Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study.","volume":"26","author":"Zhao","year":"2020"},{"issue":"1","key":"b30","series-title":"Indian J Gastroenterol","first-page":"35","article-title":"Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis.","volume":"44","author":"Kumar","year":"2025"},{"key":"b31","series-title":"Chin Gen Pract Med","first-page":"1867","article-title":"Risk factors and strategies of drug-induced liver injury in untreated pulmonary tuberculosis patients","volume":"14","author":"Mao","year":"2016"},{"key":"b32","series-title":"Front Pharmacol","first-page":"1406454","article-title":"Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury.","volume":"15","author":"Liu","year":"2024"},{"key":"b33","series-title":"Infect Drug Resist","first-page":"2065","article-title":"Clinical features of anti-tuberculosis drug-induced liver injury and risk factors for severe cases: A retrospective study in China.","volume":"18","author":"Zhang","year":"2025"},{"key":"b34","series-title":"Front Nutr","first-page":"1691359","article-title":"Nutritional risk status and related influencing factors in patients with tuberculosis complicated with type 2 diabetes mellitus.","volume":"13","author":"Cao","year":"2026"},{"key":"b35","series-title":"Infect Dis Poverty","first-page":"22","article-title":"Diabetes mellitus is associated with increased mortality during tuberculosis treatment: A prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia.","volume":"5","author":"Workneh","year":"2016"},{"issue":"4","key":"b36","series-title":"Cells","first-page":"837","article-title":"Role and mechanisms of mitophagy in liver diseases.","volume":"9","author":"Ma","year":"2020"},{"key":"b37","series-title":"Front Endocrinol (Lausanne)","first-page":"347","article-title":"Alterations in mitochondrial oxidative stress and mitophagy in subjects with prediabetes and type 2 diabetes mellitus.","volume":"8","author":"Bhansali","year":"2017"},{"issue":"5","key":"b38","series-title":"Chemotherapy","first-page":"269","article-title":"Is the prophylactic use of hepatoprotectants necessary in anti-tuberculosis treatment?","volume":"62","author":"Xu","year":"2017"},{"issue":"3","key":"b39","series-title":"Infect Med (Beijing)","first-page":"154","article-title":"Hepatoprotective drugs for prevention of liver injury resulting from anti-tuberculosis treatment: A meta-analysis of cohort studies.","volume":"1","author":"Wang","year":"2022"},{"key":"b40","series-title":"Front Pharmacol","first-page":"813682","article-title":"Effectiveness of prophylactic use of hepatoprotectants for tuberculosis drug-induced liver injury: A population-based cohort analysis involving 6,743 Chinese patients.","volume":"13","author":"Chen","year":"2022"},{"issue":"1","key":"b41","series-title":"BMC Infect Dis","first-page":"668","article-title":"Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: A retrospective analysis.","volume":"16","author":"Saito","year":"2016"},{"issue":"2","key":"b42","series-title":"J Gastroenterol Hepatol","first-page":"409","article-title":"Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.","volume":"31","author":"Zhang","year":"2016"},{"issue":"1","key":"b43","series-title":"J Med Biochem","first-page":"17","article-title":"The feasibility of using liver function indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in patients with liver disease.","volume":"44","author":"Shaoqiang","year":"2025"},{"key":"b44","series-title":"Annu Rev Pathol","first-page":"299","article-title":"The hippo pathway in liver homeostasis and pathophysiology.","volume":"16","author":"Driskill","year":"2021"},{"issue":"12","key":"b45","series-title":"PLoS One","first-page":"e27810","article-title":"Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.","volume":"6","author":"Yimer","year":"2011"},{"issue":"3","key":"b46","series-title":"CMAJ","first-page":"367","article-title":"Liver enzyme alteration: A guide for clinicians.","volume":"172","author":"Giannini","year":"2005"},{"issue":"4","key":"b47","series-title":"Clin Lab Med","first-page":"667","article-title":"Aminotransferases in disease","volume":"9","author":"Rej","year":"1989"},{"issue":"3","key":"b48","series-title":"Hepatology","first-page":"367","article-title":"Plasma clearance of intravenously injected aspartate aminotransferase isozymes: Evidence for preferential uptake by sinusoidal liver cells.","volume":"5","author":"Kamimoto","year":"1985"},{"issue":"1","key":"b49","series-title":"Paediatr Perinat Epidemiol","first-page":"12","article-title":"The associations between birthweight and adult markers of liver damage and function.","volume":"22","author":"Fraser","year":"2008"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/115\/3\/article-p475.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/115\/3\/article-p475.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/115\/3\/article-p475.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:54:17Z","timestamp":1788353657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/115\/3\/article-p475.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":49,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.25-0699","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}